Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

SIREN protocol: Impact of detectable anti-SARS-CoV-2 on the subsequent incidence of COVID-19 in 100,000 healthcare workers: do antibody positive healthcare workers have less reinfection than antibody negative healthcare workers?

S. Wallace, V. Hall, View ORCID ProfileA. Charlett, View ORCID ProfileP.D. Kirwan, M.J. Cole, M. Shrotri, S. Rokadiya, B. Oguti, A. Vusirikala, M. Zambon, T. Brooks, M. Ramsay, C.S. Brown, M.A. Chand, S. Hopkins
doi: https://doi.org/10.1101/2020.12.15.20247981
S. Wallace
COVID-19 response, Public Health England, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: sarah.wallace@phe.gov.uk
V. Hall
COVID-19 response, Public Health England, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Charlett
COVID-19 response, Public Health England, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for A. Charlett
P.D. Kirwan
COVID-19 response, Public Health England, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for P.D. Kirwan
M.J. Cole
COVID-19 response, Public Health England, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Shrotri
COVID-19 response, Public Health England, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. Rokadiya
COVID-19 response, Public Health England, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
B. Oguti
COVID-19 response, Public Health England, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Vusirikala
COVID-19 response, Public Health England, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Zambon
COVID-19 response, Public Health England, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T. Brooks
COVID-19 response, Public Health England, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Ramsay
COVID-19 response, Public Health England, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C.S. Brown
COVID-19 response, Public Health England, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M.A. Chand
COVID-19 response, Public Health England, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. Hopkins
COVID-19 response, Public Health England, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background The overall risk of reinfection in individuals who have previously had COVID-19 is unknown. To determine if prior SARS-CoV-2 infection (as determined by at least one positive commercial antibody test performed in a laboratory) in healthcare workers confers future immunity to reinfection, we are undertaking a large-scale prospective longitudinal cohort study of healthcare staff across the United Kingdom.

Methods Population and Setting: staff members of healthcare organisations working in hospitals in the UK

At recruitment, participants will have their serum tested for anti-SARS-CoV-2 at baseline and using these results will be initially allocated to either antibody positive or antibody negative cohorts. Participants will undergo antibody and viral RNA testing at 1-4 weekly intervals throughout the study period, and based on these results may move between cohorts. Any results from testing undertaken for other reasons (e.g. symptoms, contact tracing etc.) or prior to study entry will also be included. Individuals will complete enrolment and fortnightly questionnaires on exposures and symptoms. Follow-up will be for at least 12 months from study entry.

Outcome The primary outcome of interest is a reinfection with SARS -CoV-2 during the study period. Secondary outcomes will include incidence and prevalence (both RNA and antibody) of SARS-CoV-2, viral genomics, viral culture, symptom history and antibody/neutralising antibody titres.

Conclusion This large study will help us to understand the impact of the presence of antibodies on the risk of reinfection with SARS-CoV-2; the results will have substantial implications in terms of national and international policy, as well as for risk management of contacts of COVID-19 cases.

Trial Registration IRAS ID 284460, HRA and Health and Care Research Wales approval granted 22 May 2020.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

IRAS ID 284460

Funding Statement

The study is funded by the Department of Health and Social Care and Public Health England, with contributions from the Scottish, Welsh and Northern Irish governments.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Berkshire Research Ethnics Committee Approval by HRA and Health and Care Research Wales

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Not applicable

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted December 18, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
SIREN protocol: Impact of detectable anti-SARS-CoV-2 on the subsequent incidence of COVID-19 in 100,000 healthcare workers: do antibody positive healthcare workers have less reinfection than antibody negative healthcare workers?
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
SIREN protocol: Impact of detectable anti-SARS-CoV-2 on the subsequent incidence of COVID-19 in 100,000 healthcare workers: do antibody positive healthcare workers have less reinfection than antibody negative healthcare workers?
S. Wallace, V. Hall, A. Charlett, P.D. Kirwan, M.J. Cole, M. Shrotri, S. Rokadiya, B. Oguti, A. Vusirikala, M. Zambon, T. Brooks, M. Ramsay, C.S. Brown, M.A. Chand, S. Hopkins
medRxiv 2020.12.15.20247981; doi: https://doi.org/10.1101/2020.12.15.20247981
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
SIREN protocol: Impact of detectable anti-SARS-CoV-2 on the subsequent incidence of COVID-19 in 100,000 healthcare workers: do antibody positive healthcare workers have less reinfection than antibody negative healthcare workers?
S. Wallace, V. Hall, A. Charlett, P.D. Kirwan, M.J. Cole, M. Shrotri, S. Rokadiya, B. Oguti, A. Vusirikala, M. Zambon, T. Brooks, M. Ramsay, C.S. Brown, M.A. Chand, S. Hopkins
medRxiv 2020.12.15.20247981; doi: https://doi.org/10.1101/2020.12.15.20247981

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Public and Global Health
Subject Areas
All Articles
  • Addiction Medicine (70)
  • Allergy and Immunology (168)
  • Anesthesia (50)
  • Cardiovascular Medicine (450)
  • Dentistry and Oral Medicine (82)
  • Dermatology (55)
  • Emergency Medicine (157)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (191)
  • Epidemiology (5247)
  • Forensic Medicine (3)
  • Gastroenterology (195)
  • Genetic and Genomic Medicine (755)
  • Geriatric Medicine (80)
  • Health Economics (212)
  • Health Informatics (696)
  • Health Policy (356)
  • Health Systems and Quality Improvement (223)
  • Hematology (99)
  • HIV/AIDS (162)
  • Infectious Diseases (except HIV/AIDS) (5848)
  • Intensive Care and Critical Care Medicine (358)
  • Medical Education (103)
  • Medical Ethics (25)
  • Nephrology (80)
  • Neurology (762)
  • Nursing (43)
  • Nutrition (130)
  • Obstetrics and Gynecology (141)
  • Occupational and Environmental Health (231)
  • Oncology (476)
  • Ophthalmology (150)
  • Orthopedics (38)
  • Otolaryngology (95)
  • Pain Medicine (39)
  • Palliative Medicine (20)
  • Pathology (140)
  • Pediatrics (223)
  • Pharmacology and Therapeutics (136)
  • Primary Care Research (96)
  • Psychiatry and Clinical Psychology (859)
  • Public and Global Health (2004)
  • Radiology and Imaging (348)
  • Rehabilitation Medicine and Physical Therapy (158)
  • Respiratory Medicine (283)
  • Rheumatology (94)
  • Sexual and Reproductive Health (73)
  • Sports Medicine (76)
  • Surgery (109)
  • Toxicology (25)
  • Transplantation (29)
  • Urology (39)